Persistence and Evolution of Following Initiation of Highly Effective Modulator Therapy in Cystic Fibrosis

Overview

Journal mBio

Publisher American Society for Microbiology

Specialty Microbiology

Date 2024 Apr 2

PMID 38564694

Authors

Catherine R Armbruster

Yasmin K Hilliam

Anna C Zemke

Samar Atteih

Christopher W Marshall

John Moore

Junu Koirala

Leah Krainz

Jordan R Gaston

Stella E Lee

Vaughn S Cooper

Jennifer M Bomberger

Affiliations

Soon will be listed here.

Abstract

Importance: The highly effective cystic fibrosis transmembrane conductance regulator modulator therapy Elexakaftor/Tezacaftor/Ivacaftor (ETI) has changed cystic fibrosis (CF) disease for many people with cystic fibrosis. While respiratory symptoms are improved by ETI, we found that people with CF remain infected with . How these persistent and evolving bacterial populations will impact the clinical manifestations of CF in the coming years remains to be seen, but the role and potentially changing face of infection in CF should not be discounted in the era of highly effective modulator therapy.

Citing Articles

Evolutionary loss of an antibiotic efflux pump increases quorum sensing mediated virulence .

Fernandes S, Ortega H, Vaillancourt M, Galdino A, Stotland A, Mun K Res Sq. 2024; .

PMID: 39606469 PMC: 11601840. DOI: 10.21203/rs.3.rs-5391023/v1.

Highly Effective Modulator Therapy: Implications for the Microbial Landscape in Cystic Fibrosis.

Valladares K, Jones L, Barnes J, Krick S Int J Mol Sci. 2024; 25(22).

PMID: 39595943 PMC: 11594123. DOI: 10.3390/ijms252211865.

Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population.

Somerville L, Borish L, Noth I, Albon D Ther Adv Respir Dis. 2024; 18:17534666241297877.

PMID: 39543951 PMC: 11565698. DOI: 10.1177/17534666241297877.

The Challenging Life of Mutators: How Survives between Persistence and Evolution in Cystic Fibrosis Lung.

Rossitto M, Fox V, Vrenna G, Tuccio Guarna Assanti V, Essa N, Lepanto M Microorganisms. 2024; 12(10).

PMID: 39458360 PMC: 11509988. DOI: 10.3390/microorganisms12102051.

The lysogenic filamentous bacteriophage phage Pf slows mucociliary transport.

Burgener E, Cai P, Kratochvil M, Rojas-Hernandez L, Joo N, Gupta A PNAS Nexus. 2024; 3(9):pgae390.

PMID: 39301510 PMC: 11412248. DOI: 10.1093/pnasnexus/pgae390.

References

Ramos K, Pilewski J, Taylor-Cousar J . Challenges in the use of highly effective modulator treatment for cystic fibrosis. J Cyst Fibros. 2021; 20(3):381-387. PMC: 8192344. DOI: 10.1016/j.jcf.2021.01.007. View

Long D, Holmes E, Goss C, Singh P, Waalkes A, Salipante S . Cell-Free DNA Detects Lung Infection in Modulator-treated People with Cystic Fibrosis. Am J Respir Crit Care Med. 2023; 208(9):944-947. PMC: 10870864. DOI: 10.1164/rccm.202305-0844LE. View

Hisert K, Heltshe S, Pope C, Jorth P, Wu X, Edwards R . Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections. Am J Respir Crit Care Med. 2017; 195(12):1617-1628. PMC: 5476912. DOI: 10.1164/rccm.201609-1954OC. View

Mayer-Hamblett N, Nichols D, Odem-Davis K, Riekert K, Sawicki G, Donaldson S . Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design. Ann Am Thorac Soc. 2021; 18(8):1397-1405. PMC: 8513667. DOI: 10.1513/AnnalsATS.202010-1336SD. View

Atteih S, Armbruster C, Hilliam Y, Rapsinski G, Bhusal J, Krainz L . Effects of highly effective modulator therapy on the dynamics of the respiratory mucosal environment and inflammatory response in cystic fibrosis. Pediatr Pulmonol. 2024; 59(5):1266-1273. PMC: 11058019. DOI: 10.1002/ppul.26898. View